Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 10,275 shares of Mirati Therapeutics stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $18.00, for a total value of $184,950.00. Following the transaction, the senior vice president now owns 12,670 shares in the company, valued at $228,060. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Jamie Christensen also recently made the following trade(s):
- On Thursday, November 2nd, Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $104,986.00.
- On Wednesday, October 4th, Jamie Christensen sold 4,000 shares of Mirati Therapeutics stock. The shares were sold at an average price of $14.00, for a total value of $56,000.00.
- On Friday, September 15th, Jamie Christensen sold 770 shares of Mirati Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $9,240.00.
Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded down $0.05 on Tuesday, reaching $16.05. The company had a trading volume of 378,811 shares, compared to its average volume of 544,613. Mirati Therapeutics, Inc. has a fifty-two week low of $2.70 and a fifty-two week high of $19.25.
Mirati Therapeutics (NASDAQ:MRTX) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.16. analysts expect that Mirati Therapeutics, Inc. will post -2.77 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in MRTX. Bank of New York Mellon Corp raised its holdings in Mirati Therapeutics by 22.9% during the first quarter. Bank of New York Mellon Corp now owns 63,004 shares of the biotechnology company’s stock worth $328,000 after acquiring an additional 11,753 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in Mirati Therapeutics during the first quarter worth about $677,000. Renaissance Technologies LLC bought a new stake in Mirati Therapeutics during the first quarter worth about $854,000. KCG Holdings Inc. bought a new stake in Mirati Therapeutics during the first quarter worth about $106,000. Finally, LMR Partners LLP bought a new stake in Mirati Therapeutics during the second quarter worth about $236,000. Institutional investors and hedge funds own 64.73% of the company’s stock.
A number of analysts have recently commented on the company. HC Wainwright restated a “buy” rating on shares of Mirati Therapeutics in a report on Tuesday, November 7th. ValuEngine lowered Mirati Therapeutics from a “hold” rating to a “sell” rating in a report on Friday. SunTrust Banks restated a “buy” rating and issued a $13.00 price target on shares of Mirati Therapeutics in a report on Monday, October 2nd. Oppenheimer restated a “buy” rating and issued a $18.00 price target on shares of Mirati Therapeutics in a report on Wednesday, November 22nd. Finally, Citigroup restated a “buy” rating and issued a $16.00 price target (up from $8.00) on shares of Mirati Therapeutics in a report on Tuesday, September 19th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company. Mirati Therapeutics currently has an average rating of “Buy” and an average price target of $13.71.
TRADEMARK VIOLATION WARNING: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/12/05/insider-selling-mirati-therapeutics-inc-mrtx-svp-sells-184950-00-in-stock.html.
About Mirati Therapeutics
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.